2,000
Participants
Start Date
May 28, 2025
Primary Completion Date
April 21, 2032
Study Completion Date
April 21, 2032
Standard of care
"2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum"
Oteseconazole - antifungal therapy 1
"Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)~* Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.~* Liposomal Amphotericin B 10 mg/kg IV once.~* No fluconazole or 5FC to be given."
Sfu-AM2-19 Injection - antifungal therapy 2
Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
Antifungal therapy 3
To be determined
Antifungal therapy 4
To be determined
RECRUITING
Infectious Diseases Institute, Kampala
RECRUITING
Mbarara University of Science and Technology, Mbarara
University of Minnesota
OTHER